Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia



Status:Recruiting
Conditions:Blood Cancer, Lymphoma, Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:1 - 21
Updated:3/3/2019
Start Date:June 5, 2017
End Date:September 30, 2019

Use our guide to learn which trials are right for you!

A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients
with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come
back or does not respond to treatment. Immunotoxins, such as inotuzumab ozogamicin, are
antibodies linked to a toxic substance and may help find cancer cells that express CD22 and
kill them without harming normal cells.

PRIMARY OBJECTIVES:

I. To determine the morphologic response rate (complete response [CR] + complete response
with incomplete hematologic recovery [CRi]) following one cycle of treatment with inotuzumab
ozogamicin (InO) in children with relapsed or refractory CD22+ B acute lymphoblastic leukemia
(B-ALL).

SECONDARY OBJECTIVES:

I. To determine the CR/CRi rate following 2 cycles of InO therapy. II. To determine the
safety of single agent InO administered at the adult recommended phase 2 dose (RP2D) to
pediatric patients with relapsed or refractory CD22+ B-ALL.

III. To determine the level of minimal residual disease (MRD) by flow cytometry in responding
patients.

IV. To determine the incidence, severity, and outcomes of sinusoidal obstruction syndrome
(SOS) of the liver in patients during InO therapy and following subsequent treatment,
including myeloablative hematopoietic stem cell transplantation (HSCT).

V. To estimate the 3-year event-free survival (EFS), 3-year overall survival (OS), and among
responders duration of CR/CRi for pediatric patients with relapsed or refractory B-ALL
treated with InO.

VI. To describe InO pharmacokinetics and immunogenicity in pediatric patients in the presence
of overt leukemia and in remission.

EXPLORATORY OBJECTIVES:

I. To describe the levels of leukemic blast CD22 surface expression and site density, and to
explore the correlation with cytogenetics and clinical outcomes after treatment with InO.

II. To explore potential mechanisms of resistance to InO therapy including CD22 splice
variants and intracellular signaling pathways.

III. To explore the impact of InO on humoral immune function and peripheral B cell
populations.

IV. To describe the level of MRD by next-generation high-throughput sequencing (HTS)
techniques which may detect low level leukemic blast populations that have altered CD22
expression.

V. To prospectively explore candidate SOS biomarkers including the endothelial marker of
inflammation Angiopoietin 2 (Ang2) and the hepatic specific complement marker L-ficolin.

VI. To explore the use of prophylactic ursodeoxycholic acid (UDCA) to prevent hepatic damage
and SOS during InO therapy and subsequent HSCT.

OUTLINE:

Patients receive inotuzumab ozogamicin intravenously (IV) over 60 minutes on days 1, 8, and
15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression
or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days, every 3 months for
1 year, and then yearly for 4 years.

Inclusion Criteria:

- Patients must have B-ALL, or previously diagnosed B lymphoblastic lymphoma (B-LL),
with >= 5% (M2 or M3) bone marrow blasts with or without extramedullary disease

- NOTE: Relapsed patients previously diagnosed with B-lymphoblastic lymphoma (B-LL)
are eligible if they have an M2 or M3 marrow at the time of enrollment on this
study

- Patients with ALL or B-LL who have M2 morphology must have local confirmatory testing
showing >= 5% blasts by flow cytometry, fluorescence in situ hybridization (FISH)
testing or other molecular method

- Leukemic blasts must demonstrate surface expression of CD22 at the time of relapse by
local/institutional flow cytometry of a bone marrow aspirate sample; (assessment of
CD22 using a bright fluorophore such as phycoerythrin [PE] is strongly recommended)

- In the case of an inadequate aspirate sample (dry tap) or if bone marrow aspirate
is unable to be performed due to patient clinical status, flow cytometry of
peripheral blood specimen may be substituted if the patient has at least 1000/uL
circulating blasts; alternatively, CD22 expression may be documented by
immunohistochemistry of a bone marrow biopsy specimen

- Patients with and without Down syndrome are eligible and must have one of the
following:

- Second or greater relapse;

- Primary refractory disease with at least 2 prior induction attempts;

- First relapse refractory to at least one prior re-induction attempt

- Any relapse after HSCT

Patients with Down syndrome are also eligible with:

- First relapse with no prior re-induction attempt

- Patients with Philadelphia chromosome (Ph)+ ALL must have had two prior therapy
attempts including two different tyrosine kinase inhibitors (TKIs)

- Patients must have fully recovered from the acute non-hematologic toxic effects
of all prior anti-cancer therapy, defined as resolution of all such toxicities to
=< grade 2 or lower per the inclusion/exclusion criteria prior to entering this
study

- Myelosuppressive chemotherapy:

- No waiting period will be required for patients receiving standard
"maintenance-like" chemotherapy including oral mercaptopurine, weekly low-dose
oral methotrexate, and intermittent vincristine; otherwise, at least 14 days must
have elapsed since the completion of cytotoxic therapy, with the exceptions of
hydroxyurea or corticosteroids used for cytoreduction

- Intrathecal cytotoxic therapy: No waiting period is required for patients having
received intrathecal cytarabine, methotrexate, and/or hydrocortisone; intrathecal
chemotherapy given at the time of diagnostic lumbar puncture (LP) to evaluate for
relapse prior to study enrollment is allowed

- At least 7 days must have elapsed since the completion of therapy with a growth
factor; at least 14 days must have elapsed after receiving pegfilgrastim

- At least 7 days must have elapsed since completion of therapy with a biologic agent
(including tyrosine kinase inhibitors); for agents that have known adverse events
occurring beyond 7 days after administration, this period prior to enrollment must be
extended beyond the time during which adverse events are known to occur

- At least 3 half-lives must have elapsed since prior therapy that included a monoclonal
antibody with the exception of blinatumomab; patients must have been off blinatumomab
infusion for at least 3 days and all drug related toxicity must have resolved to grade
2 or lower as outlined in the inclusion/exclusion criteria

- >= 2 weeks must have elapsed since local palliative radiation therapy (XRT) (small
port); >= 3 months must have elapsed if prior cranial or craniospinal XRT was
received, if >= 50% of the pelvis was irradiated, or if total-body irradiation (TBI)
was received; >= 6 weeks must have elapsed if other substantial bone marrow
irradiation was given

- At least 90 days must have elapsed since stem cell transplant and at least 30 days
from donor lymphocyte infusion; patient must have had no more than one previous HSCT
and currently have no evidence of active graft versus (vs.) host disease (GVHD)

- At least 30 days must have elapsed from the last chimeric antigen receptor (CAR)-T
cell infusion

- Patients must have a performance status corresponding to Eastern Cooperative
Oncology Group (ECOG) scores of 0, 1, or 2; use Karnofsky for patients > 16 years
of age and Lansky for patients =< 16 years of age; patients who are unable to
walk because of paralysis, but who are up in a wheelchair, will be considered
ambulatory for the purpose of assessing the performance score

- Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
mL/min/1.73 m^2 or

- A serum creatinine based on age/gender as follows:

- 1 to < 2 years: maximum serum creatinine 0.6 mg/dL (both male and female)

- 2 to < 6 years: maximum serum creatinine 0.8 mg/dL (both male and female)

- 6 to < 10 years: maximum serum creatinine 1 mg/dL (both male and female)

- 10 to < 13 years: maximum serum creatinine 1.2 mg/dL (both male and female)

- 13 to < 16 years: maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female)

- >= 16 years: maximum serum creatinine 1.7 mg/dL (male), 1.4 mg/dL (female)

- Direct bilirubin =< 1.5 x upper limit of normal (ULN) for age, and

- Serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 5
x ULN for age; for the purpose of this study, the ULN for ALT will be 45 U/L

Exclusion Criteria:

- Patients with any prior history of SOS irrespective of severity

- Patients with isolated central nervous system (CNS), testicular, or other
extramedullary site of relapse

- Patients who have been previously treated with inotuzumab ozogamicin

- History of allergic reaction attributed to compounds of similar or biologic
composition to inotuzumab ozogamicin or other agents in the study

- Patients with active optic nerve and/or retinal involvement are not eligible; patients
who are presenting with visual disturbances should have an ophthalmologic exam and, if
indicated, a magnetic resonance imaging (MRI) to assess optic nerve or retinal
involvement

- Patients who are currently receiving another investigational drug

- Patients who are currently receiving or plan to receive other anti-cancer agents
(except hydroxyurea, which may be continued until 24 hours prior to start of protocol
therapy and intrathecal chemotherapy)

- Anti-GVHD or agents to prevent organ rejection post-transplant; patients who are
receiving cyclosporine, tacrolimus, or other agents to prevent either
graft-versus-host disease post bone marrow transplant or organ rejection
post-transplant are not eligible for this trial; at least 3 half-lives must have
elapsed after the last dose of GVHD medications (meds)

- Patients who are currently receiving or plan to receive corticosteroids except as
described below

- Systemic corticosteroids may be administered for cytoreduction up to 24 hours
prior to the start of protocol therapy, as a premedication for InO and as
treatment for allergic reactions or for physiologic replacement/stress dosing of
hydrocortisone for documented adrenal insufficiency; corticosteroids are not
allowed for other indications

- Patients with known human immunodeficiency virus (HIV), hepatitis B or C infections;
testing to prove negative status is not required for enrollment unless it is deemed
necessary for usual medical care of the patient

- Patients who have an active uncontrolled infection defined as:

- Positive bacterial blood culture within 48 hours of study enrollment;

- Fever above 38.2 degree Celsius (C) within 48 hours of study enrollment with
clinical signs of infection; fever that is determined to be due to tumor burden
is allowed if patients have documented negative blood cultures for at least 48
hours prior to enrollment and no concurrent signs or symptoms of active infection
or hemodynamic instability

- A positive fungal culture within 30 days of study enrollment or active therapy
for presumed invasive fungal infection

- Patients may be receiving IV or oral antibiotics to complete a course of therapy
for a prior documented infection as long as cultures have been negative for at
least 48 hours and signs or symptoms of active infection have resolved; for
patients with clostridium (c.) difficile diarrhea, at least 72 hours of
antibacterial therapy must have elapsed and stools must have normalized to
baseline

- Active viral or protozoal infection requiring IV treatment

- Patients known to have one of the following concomitant genetic syndromes: Bloom
syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman
syndrome, or any other known bone marrow failure syndrome

- Women of childbearing potential should be advised to avoid becoming pregnant while
receiving InO; women should not breast-feed during treatment with InO and for at least
2 months after the final dose

- Female patients of childbearing potential are not eligible unless a negative
pregnancy test result has been obtained within 7 days of starting protocol
therapy

- Female patients who are sexually active and of reproductive potential are not
eligible unless they agree to use an effective contraceptive method for the
duration of their study participation and for 8 months after the last dose of InO

- Men with female partners of childbearing potential should use effective
contraception during treatment with InO and for at least 5 months after the last
dose of InO

- Lactating females are not eligible unless they agree not to breastfeed their
infants
We found this trial at
129
sites
Sacramento, California 95817
Principal Investigator: Marcio H. Malogolowkin
Phone: 916-734-3089
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
4900 Mueller Boulevard
Austin, Texas 78723
(512) 324-0000
Principal Investigator: Amy C. Fowler
Dell Children's Medical Center of Central Texas Welcome to Dell Children
?
mi
from
Austin, TX
Click here to add this to my saved trials
1600 7th Avenue
Birmingham, Alabama 35233
(205) 638-9100
Principal Investigator: Matthew A. Kutny
Children's Hospital of Alabama Children
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Clare J. Twist
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1 South Prospect Street
Burlington, Vermont 05401
802-656-8990
Principal Investigator: Jessica L. Heath
?
mi
from
Burlington, VT
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: William C. Petersen
Phone: 434-243-6303
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Principal Investigator: Maureen M. O'Brien
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
700 Childrens Drive
Columbus, Ohio 43205
(616) 722-2000
Principal Investigator: Mark A. Ranalli
Nationwide Children's Hospital At Nationwide Children’s, we are creating the future of pediatric health care....
?
mi
from
Columbus, OH
Click here to add this to my saved trials
3533 South Alameda Street
Corpus Christi, Texas 78411
(361) 694-5000
Principal Investigator: Nkechi I. Mba
Driscoll Children's Hospital Driscoll Children's Hospital was built because Clara Driscoll's will requested that a...
?
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
7777 Forest Ln # C840
Dallas, Texas 75230
(972) 566-7000
Principal Investigator: Stanton C. Goldman
Phone: 972-566-5588
Medical City Dallas Hospital If you have concerns for your health, that of a family...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
1200 Pleasant Street
Des Moines, Iowa 50309
(515) 241-KIDS
Principal Investigator: Wendy L. Woods-Swafford
Blank Children's Hospital Blank Children's Hospital is completely dedicated to meeting the unique health care...
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
(626) 256-4673
Principal Investigator: Weili Sun
Phone: 800-826-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
100 Michigan Street Northeast
Grand Rapids, Michigan 49503
616.391.9000
Principal Investigator: Kathleen J. Yost
Helen DeVos Children's Hospital at Spectrum Health Helen DeVos Children's Hospital, located in Grand Rapids,...
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
282 Washington St
Hartford, Connecticut 06106
(860) 545-9000
Principal Investigator: Michael S. Isakoff
Connecticut Children's Medical Center Connecticut Children’s Medical Center is a nationally recognized, 187-bed not-for-profit children’s...
?
mi
from
Hartford, CT
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Anderson (Andy) B. Collier
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
4650 Sunset Blvd
Los Angeles, California 90027
 (323) 660-2450
Principal Investigator: Leo Mascarenhas
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
262 Danny Thomas Pl
Memphis, Tennessee 38105
(901) 495-3300
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
?
mi
from
Memphis, TN
Click here to add this to my saved trials
601 Children's Lane
Norfolk, Virginia 23507
(757) 668-7000
Principal Investigator: Eric J. Lowe
Children's Hospital of The King's Daughters Children
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
747 52nd St
Oakland, California 94609
(510) 428-3000
Principal Investigator: Carla B. Golden
Children's Hospital and Research Center Oakland For nearly 100 years, Children's Hospital & Research Center...
?
mi
from
Oakland, CA
Click here to add this to my saved trials
1201 W La Veta Ave
Orange, California 92868
(714) 997-3000
Principal Investigator: Elyssa M. Rubin
Children's Hospital of Orange County For more than 45 years, CHOC Children’s has been steadfastly...
?
mi
from
Orange, CA
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Principal Investigator: Susan R. Rheingold
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
412-692-5325
Principal Investigator: Andrew Bukowinski
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: Bill H. Chang
Phone: 503-494-1080
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
593 Eddy Street
Providence, Rhode Island 02903
401-444-4000
Principal Investigator: Jennifer J. Greene Welch
Phone: 401-444-1488
Rhode Island Hospital Founded in 1863, Rhode Island Hospital in Providence, RI, is a private,...
?
mi
from
Providence, RI
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Angela R. Girvin
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
7700 Floyd Curl Dr
San Antonio, Texas 78229
(210) 575-7000
Principal Investigator: Vinod K. Gidvani-Diaz
Methodist Children's Hospital of South Texas Methodist Children
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
3020 Childrens way
San Diego, California 92123
(858) 576-1700
Principal Investigator: William D. Roberts
Rady Children's Hospital - San Diego Rady Children's Hospital-San Diego is the region’s pediatric medical...
?
mi
from
San Diego, CA
Click here to add this to my saved trials
40 Sunshine Cottage Road
Valhalla, New York 10595
(914) 594-4000
Principal Investigator: Jessica C. Hochberg
Phone: 914-594-3794
New York Medical College The College was founded in 1860 by a group of New...
?
mi
from
Valhalla, NY
Click here to add this to my saved trials
1600 Rockland Road
Wilmington, Delaware 19803
(302) 651-4200
Principal Investigator: Emi H. Caywood
Phone: 302-651-6884
Alfred I. duPont Hospital for Children Nemours began more than 70 years ago with the...
?
mi
from
Wilmington, DE
Click here to add this to my saved trials
Akron, Ohio 44308
Principal Investigator: Steven J. Kuerbitz
?
mi
from
Akron, OH
Click here to add this to my saved trials
Albany, New York 12208
Principal Investigator: Kenneth G. Lucas
Phone: 518-262-5513
?
mi
from
Albany, NY
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
?
mi
from
Allentown, PA
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Brenda J. Wittman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
1540 East Hospital Drive
Ann Arbor, Michigan 48109
(877) 475-6688
Principal Investigator: Rajen Mody
C S Mott Children's Hospital Behind the doors of C.S. Mott Children's Hospital there exist...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Asheville, North Carolina 28801
Principal Investigator: Douglas J. Scothorn
Phone: 828-213-4150
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Melinda G. Pauly
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
13123 E 16th Ave
Aurora, Colorado 80045
(720) 777-1234
Principal Investigator: Kelly W. Maloney
Children's Hospital Colorado At Children's Hospital Colorado, we see more, treat more and heal more...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
2401 W Belvedere Ave
Baltimore, Maryland 21215
(410) 601-9000
Principal Investigator: Jason M. Fixler
Phone: 410-601-6120
Sinai Hospital of Baltimore Sinai Hospital of Baltimore provides a broad array of high-quality, cost-effective...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Patrick A. Brown
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Nadine P. SantaCruz
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
?
mi
from
Bangor, ME
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Eugenia Chang
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
?
mi
from
Boise, ID
Click here to add this to my saved trials
Boston, Massachusetts 02111
Principal Investigator: Michael J. Kelly
Phone: 617-636-5535
?
mi
from
Boston, MA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Lewis B. Silverman
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Caguas, 00726
Principal Investigator: Jhon A. Guerra
Phone: 787-653-3434
?
mi
from
Caguas,
Click here to add this to my saved trials
Chicago, Illinois 60614
Principal Investigator: Nobuko Hijiya
?
mi
from
Chicago, IL
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
Principal Investigator: Jennifer L. McNeer
Phone: 773-702-8222
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2049 E 100th St
Cleveland, Ohio 44106
(216) 444-2200
Principal Investigator: Rabi Hanna
Phone: 866-223-8100
Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Columbia, Missouri 65201
Principal Investigator: Barbara A. Gruner
?
mi
from
Columbia, MO
Click here to add this to my saved trials
5 Richland Medical Park Dr
Columbia, South Carolina 29203
(803) 434-7000
Principal Investigator: Stuart L. Cramer
Phone: 803-434-3680
Palmetto Health Richland Palmetto Health Richland, originally founded in 1892 as Columbia Hospital, has a...
?
mi
from
Columbia, SC
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Tamra L. Slone
Phone: 214-648-7097
?
mi
from
Dallas, TX
Click here to add this to my saved trials
100 North Academy Avenue
Danville, Pennsylvania 17822
570-271-6211
Principal Investigator: Jagadeesh Ramdas
Phone: 570-271-5251
Geisinger Medical Center Since 1915, Geisinger Medical Center has been known as the region’s resource...
?
mi
from
Danville, PA
Click here to add this to my saved trials
Dayton, Ohio 45404
Principal Investigator: Ayman A. El-Sheikh
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Denver, Colorado 80218
Principal Investigator: Jennifer J. Clark
?
mi
from
Denver, CO
Click here to add this to my saved trials
9333 Imperial Highway
Downey, California 90242
Principal Investigator: Robert M. Cooper
Phone: 510-891-3400
?
mi
from
Downey, CA
Click here to add this to my saved trials
El Paso, Texas 79905
Principal Investigator: Lisa L. Hartman
?
mi
from
El Paso, TX
Click here to add this to my saved trials
801 Broadway North
Fargo, North Dakota 58122
Principal Investigator: Samuel O. Anim
Phone: 800-437-4010
?
mi
from
Fargo, ND
Click here to add this to my saved trials
Fort Myers, Florida 33908
Principal Investigator: Emad K. Salman
?
mi
from
Fort Myers, FL
Click here to add this to my saved trials
801 7th Avenue
Fort Worth, Texas 76104
(682) 885-4000
Principal Investigator: Kenneth M. Heym
Cook Children's Medical Center Cook Children's Health Care System is a not-for-profit, nationally recognized pediatric...
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
1600 Southwest Archer Road
Gainesville, Florida 32610
Principal Investigator: William B. Slayton
Phone: 352-273-8010
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
1001 E 5th St
Greenville, North Carolina 27858
(252) 328-6131
Principal Investigator: Andrea R. Whitfield
Phone: 252-744-1015
East Carolina University Whether it's meeting the demand for more teachers and healthcare professionals or...
?
mi
from
Greenville, NC
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
(201) 996-2000
Principal Investigator: Burton E. Appel
Phone: 201-996-2879
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
Principal Investigator: Lisa M. McGregor
?
mi
from
Hershey, PA
Click here to add this to my saved trials
Hollywood, Florida 33021
Principal Investigator: Iftikhar Hanif
?
mi
from
Hollywood, FL
Click here to add this to my saved trials
1319 Punahou St
Honolulu, Hawaii 96826
(808) 983-6000
Kapiolani Medical Center for Women and Children Hawai‘i Pacific Health is an integrated health care...
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Joanna S. Yi
Phone: 713-798-1354
?
mi
from
Houston, TX
Click here to add this to my saved trials
705 Riley Hospital Dr
Indianapolis, Indiana 46202
(317) 944-5000
Principal Investigator: Kamnesh R. Pradhan
Phone: 800-248-1199
Riley Hospital for Children Riley Hospital for Children at IU Health is a place of...
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Indianapolis, Indiana 46260
Principal Investigator: Bassem I. Razzouk
Phone: 317-338-2194
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Iowa City, Iowa 52242
Principal Investigator: Mariko Sato
Phone: 800-237-1225
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Jacksonville, Florida 32207
Principal Investigator: Emi H. Caywood
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Kansas City, Missouri 64108
Principal Investigator: Jaszianne A. Tolbert
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Las Vegas, Nevada 89109
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Las Vegas, Nevada 89135
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Las Vegas, Nevada 89144
Principal Investigator: Alan K. Ikeda
Phone: 702-384-0013
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
1 Medical Center Dr
Lebanon, New Hampshire 03756
 (603) 650-5000
Principal Investigator: Julie Kim
Phone: 800-639-6918
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
?
mi
from
Lebanon, NH
Click here to add this to my saved trials
Lexington, Kentucky
Principal Investigator: Vlad C. Radulescu
Phone: 859-257-3379
?
mi
from
Lexington, KY
Click here to add this to my saved trials
1 Children's Way
Little Rock, Arkansas 72202
(501) 364-1100
Principal Investigator: David L. Becton
Arkansas Children's Hospital Arkansas Children's Hospital (ACH) is the only pediatric medical center in Arkansas...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
11234 Anderson St
Loma Linda, California 92354
(909) 558-4000
Principal Investigator: Albert Kheradpour
Phone: 909-558-3375
Loma Linda University Medical Center An outgrowth of the original Sanitarium on the hill in...
?
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Louisville, Kentucky 40202
Principal Investigator: Ashok B. Raj
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Lubbock, Texas 79430
Principal Investigator: Mohamad M. Al-Rahawan
?
mi
from
Lubbock, TX
Click here to add this to my saved trials
Madera, California 93638
Principal Investigator: Vonda L. Crouse
?
mi
from
Madera, CA
Click here to add this to my saved trials
Marshfield, Wisconsin 54449
?
mi
from
Marshfield, WI
Click here to add this to my saved trials
2160 South 1st Avenue
Maywood, Illinois 60153
(888) 584-7888
Principal Investigator: Eugene Suh
Phone: 708-226-4357
Loyola University Medical Center Loyola University Health System is committed to excellence in patient care...
?
mi
from
Maywood, IL
Click here to add this to my saved trials
Mesa, Arizona 85202
Principal Investigator: Hardeo K. Panchoosingh
?
mi
from
Mesa, AZ
Click here to add this to my saved trials
Miami, Florida 33155
Principal Investigator: Enrique A. Escalon
?
mi
from
Miami, FL
Click here to add this to my saved trials
9000 W Wisconsin Ave #270
Milwaukee, Wisconsin 53226
(414) 266-2000
Principal Investigator: Michael J. Burke
Phone: 414-955-4727
Children's Hospital of Wisconsin Nothing matters more than our children. At Children's Hospital of Wisconsin,...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
259 1st Street
Mineola, New York 11501
Principal Investigator: Mark E. Weinblatt
Phone: 866-946-8476
?
mi
from
Mineola, NY
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
Principal Investigator: Peter M. Gordon
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
2525 Chicago Ave
Minneapolis, Minnesota 55404
(612) 813-6000
Principal Investigator: Michael K. Richards
Children's Hospitals and Clinics of Minnesota - Minneapolis Children's Hospitals and Clinics of Minnesota is...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Morgantown, West Virginia 26505
Principal Investigator: Stephan R. Paul
Phone: 304-293-7374
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
Morristown, New Jersey 07962
Principal Investigator: Steven L. Halpern
Phone: 973-971-5900
?
mi
from
Morristown, NJ
Click here to add this to my saved trials
Nashville, Tennessee 37203
Principal Investigator: Haydar A. Frangoul
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Nashville, Tennessee 37232
Principal Investigator: Debra L. Friedman
Phone: 800-811-8480
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Brunswick, New Jersey 08903
Principal Investigator: Archana Sharma
Phone: 732-235-8675
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
New Hyde Park, New York 11040
Principal Investigator: Julie I. Krystal
?
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
New Orleans, Louisiana 70121
Principal Investigator: Craig Lotterman
Phone: 504-703-8712
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
New York, New York 10016
Principal Investigator: Sharon L. Gardner
Phone: 212-263-4434
?
mi
from
New York, NY
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Kavitha Ramaswamy
Phone: 212-639-7592
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
201 Lyons Ave
Newark, New Jersey 07112
(973) 926-7000
Principal Investigator: Teena Bhatla
Phone: 973-926-7230
Newark Beth Israel Medical Center Newark Beth Israel Medical Center, a regional care, teaching hospital...
?
mi
from
Newark, NJ
Click here to add this to my saved trials
Oakland, California 94611
Principal Investigator: Laura A. Campbell
Phone: 877-642-4691
?
mi
from
Oakland, CA
Click here to add this to my saved trials
940 NE 13th St
Oklahoma City, Oklahoma 73190
(405) 271-6458
Principal Investigator: Rene Y. McNall-Knapp
Phone: 405-271-8777
University of Oklahoma Health Sciences Center The OU Health Sciences Center is composed of seven...
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
8200 Dodge St
Omaha, Nebraska 68114
(402) 955-5400
Principal Investigator: Minnie Abromowitch
Children's Hospital and Medical Center of Omaha Children's Hospital & Medical Center has a rich...
?
mi
from
Omaha, NE
Click here to add this to my saved trials